Similar articles

• Cyclosporine-induced elevation in circulating endothelin-1 in patients with solid-organ transplants.

  Grieff M, Loertscher R, Shohaib SA, Stewart DJ. Grieff M, et al. Transplantation. 1993 Oct;56(4):880-4. doi: 10.1097/00007890-199310000-00021. Transplantation. 1993. PMID: 8212211
• Conversion from standard cyclosporine to low-dose cyclosporine and azathioprine therapy as treatment for cyclosporine-related complications in liver transplant patients.

  Perkins JD, Sterioff S, Wiesner RH, Offord KP, Rakela J, Dickson ER, Krom RA. Perkins JD, et al. Transplant Proc. 1987 Feb;19(1 Pt 3):2434-6. Transplant Proc. 1987. PMID: 3274533 No abstract available.
• Role of immunosuppressive therapy in neuroendocrine activation after human heart, renal, and liver transplantation.

  Piquard F, Geny B, Elero B, Canguilhem B, Mettauer B, Epailly E, Chakfe N, Charpentier A, Wolf P, Kretz JG, Eisenmann B, Koehl C, Haberey P. Piquard F, et al. Transplant Proc. 1998 Aug;30(5):2124-6. doi: 10.1016/s0041-1345(98)00561-2. Transplant Proc. 1998. PMID: 9723414 No abstract available.
• Cyclosporine: a new immunosuppressive agent for organ transplantation.

  Cohen DJ, Loertscher R, Rubin MF, Tilney NL, Carpenter CB, Strom TB. Cohen DJ, et al. Ann Intern Med. 1984 Nov;101(5):667-82. doi: 10.7326/0003-4819-101-5-667. Ann Intern Med. 1984. PMID: 6385799 Review.
• Immunosuppressive drugs.

  Bowman H, Lennard TW. Bowman H, et al. Br J Hosp Med. 1992 Nov 4-17;48(9):570-3, 576-9. Br J Hosp Med. 1992. PMID: 1282440 Review.